A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
Phase of Trial: Phase I/II
Latest Information Update: 20 Apr 2016
At a glance
- Drugs Carotuximab (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 20 Apr 2016 Results (n = 20) presented at the 107th Annual Meeting of the American Association for Cancer Research.
- 11 Apr 2016 Data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2016, according to a TRACON Pharmaceuticals media release.
- 12 Feb 2015 Treatment arms changed from 2 to 6, dose 20mg is included now. Also focused is only AR now as (progression free survival) primary end point is deleted.